Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reiterated by equities researchers at Piper Jaffray Companies in a research note issued on Monday, Stock Target Advisor reports. They currently have a $104.00 price target on the stock. Piper Jaffray Companies’ target price indicates a potential upside of 57.70% from the stock’s current price.
Other research analysts have also issued research reports about the stock. Roth Capital raised their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Chardan Capital reaffirmed a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Goldman Sachs Group raised their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, Oppenheimer raised their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $69.54.
Shares of NASDAQ:CRSP opened at $65.95 on Monday. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company’s 50-day moving average price is $61.00 and its two-hundred day moving average price is $49.02. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market cap of $3.61 billion, a P/E ratio of -19.17 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, equities analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 in the last three months. 21.40% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. NEXT Financial Group Inc boosted its stake in Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the last quarter. Benjamin Edwards Inc. boosted its stake in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. acquired a new stake in Crispr Therapeutics during the 3rd quarter worth approximately $26,000. US Bancorp DE raised its holdings in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the period. Finally, BSW Wealth Partners acquired a new stake in Crispr Therapeutics during the 2nd quarter worth approximately $39,000. 49.82% of the stock is currently owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.